of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes
(important mediators of inflammation involved in the development and
progression of atherosclerosis). VIA-2291 is being developed as a
once-daily, oral drug to target inflammation in the blood vessel wall,
thereby potentially decreasing the risk of major adverse cardiovascular
events, including heart attack and stroke. According to the American Heart
Association, 15.8 million patients in the U.S. have coronary artery
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the
development of compounds for the treatment of cardiovascular disease. VIA
is building a pipeline of small-molecule drugs that target a significant
unmet medical need: reducing inflammation in the blood vessel wall, which
is an underlying cause of atherosclerosis and its complications, including
heart attack and stroke. The company's lead drug candidate, VIA-2291, is in
multiple Phase II clinical studies in patients with cardiovascular disease.
For more information, visit: http://www.viapharmaceuticals.com.
This press release may contain "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or to VIA's future financial performance
and involve known and unknown risks, uncertainties and other factors that
may cause VIA's actual results, levels of activity, performance or
achievements to be expressed or implied by these forward-looking
statements. In some cases, you can identify forward-looking statements by
the use of words such as "may," "could," "expect," "intend," "plan,"
"seek," "anticipate," "believe," "estimate," "predict," "potential,"
"continue" or the negative of these terms or other comparable terminology.
You should not place undue reliance on forward-looking
Page: 1 2 3 4 Related biology technology :1
|SOURCE VIA Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes2
. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results3
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML4
. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20075
. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results6
. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences7
. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer8
. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences9
. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals10
. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)11
. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs